A carregar...
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
OBJECTIVES: Tenapanor is a first-in-class, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger NHE3. This study assessed the efficacy and safety of tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). METHODS: In this phase 2, double-blind stud...
Na minha lista:
| Publicado no: | Am J Gastroenterol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5418559/ https://ncbi.nlm.nih.gov/pubmed/28244495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ajg.2017.41 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|